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1. Introduction 
Gastrointestinal stromal tumours (GISTs) represent the most common non-epithelial 
mesenchymal tumours of the gastrointestinal tract. The role of the pathologist in the 
differential diagnosis of GISTs, as well as the correct understanding of these neoplasia by 
detailed clinicopathologic, biological and genetic studies, are becoming increasingly 
important in optimizing the management of these tumours and to develop new therapies for 
the treatment of advanced diseases.  
2. Historical overview 
At the beginning there were more misunderstandings about GIST. On the basis of light 
microscopic descriptions and until 1960, Gastrointestinal Stromal Tumors (GISTs) were 
though to be neoplasms of smooth muscle origin; so they were classified as leiomyoma, 
leyomiosarcoma or leyomioblastoma, in one word STUMP (Smooth-muscle Tumors of 
Undetermined malignant Potential). In the early 1970s, electron microscopic studies 
revealed inconsistent evidence of smooth muscle differentiation. During ‘80s, this data was 
supported by the application of immunohistochemical studies, which showed that the 
expression of muscle markers (such as actins and desmins) was far more variable than those 
observed in smooth muscle tumors arising from the myometrium. Immunohistochemistry 
also demonstrated the existence of a subset of stromal neoplasia having neural crest 
immunophenotype (S100- and neuron-specific enolase – NSE-positivity) which has not been 
found in other smooth muscle neoplasms. These findings switched on a long-standing 
debate about the real origin and nature of mesenchymal tumors arising within the gut wall. 
In 1983, Mazur and Clark postulated the derivation of these “stromal tumors” from 
mesenchymal stem element, considered to be the progenitor of both spindle and epithelioid 
cells, and showing CD34 positivity. In 90s, it began to refer to “GISTs” to collectively 
designate a group of mesenchymal tumours with miogenic or neurogenic differentiation, 
arising from gastrointestinal tract, separate from stromal tumors taking place of other sites 
(e.g. uterus). The observation of both smooth muscle characteristics and neural features in 
GISTs, led to the conclusion that these tumour would be related to a little population of 
spindle cells placed in the gut wall. So, in 1998 Kindblom et al, definitively defined the 
origin of GISTs from a pluripotential stem cell, programmed to differentiate into either 
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Intestitial Cajal Cell (ICC) and smooth muscle cells. They represent ICCs as a network of 
cellular elements, intercalated between nerve fibres and muscle cells, involved in the 
generation of gut contraction (Figure 1). 
 
 
Fig. 1. Cajal cell (arrow) within gastrointestinal wall 
Successive studies performed on ICCs demonstrated their growth depending on stem cell 
factor signalling through KIT tyrosine kinase (CD117) (Isozaki et al., 1995). In 1998, 
publications by Hirota et al., and Kindblom et al., announced to scientific community the 
expression of CD117 on GISTs (Kingblom et al., 1998; Miettinen et al., 2005 ). 
Starting from this point, Ogasawara et al. assigned to c-kit mutation of ICC an early causal 
role in GIST tumorigenesis and Agaimy et al. defined GIST as the grossly identifiable 
counterpart of sporadic ICC hyperplasia.  
In subsequent years and to these days, all the previous observations led to the correct 
classification of GISTs (CD117-positive) as a separate entity from smooth muscle neoplasia 
(CD117-negative) and to the development of a target-therapy for this disease.  
3. c-kit gene, KIT receptor and kit mutations 
The c-kit gene is the cellular homologue of the oncogene v-kit of HZ4 feline sarcoma virus, 
encoding a type III receptor protein-tyrosine kinase (KIT). The type III class of receptors also 
includes the plateled-derivated growth factor receptors, ǂ and ǃ-chain (PDGFRǂ, PDGFRǃ), 
the macrophage colony-stimulating factor (M-CSF) receptor and the FI cytokine receptor (Flt3). 
All protein-tyrosine kinase receptors share the same topology: an extracellular ligand-
binding domain, made up five immunoglobulin-like repeats, a single transmembrane 
sequence, a juxtamembrane domain, that is considered to be significant for regulation of KIT 
dimerization and in the inhibition of kinase activity, and a cytoplasmic kinase domain 
(Figure 2). The structure and amino-acid sequence of KIT is well preserved in humans, 
mices and rats.  
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Fig. 2. KIT receptor structure and distribution of KIT mutations 
The ligand for KIT is named Stem Cell Factor (SCF); it binds to the second and third 
immunoglobulin domains, playing the fourth domain a role in receptor dimerization 
(Zhang et al., 2000). Two molecules of wild-type KIT form a dimer by binding two 
molecules of SCF; dimerization leads to autophosphorylation of KIT on tyrosine kinase 
domain and to activation of protein kinase activity through several signal transduction 
systems, such as phosphatidylinositol 3-kinase (PI3K)/Akt pathway, Ras/mitogen activated 
protein kinase (MAPK) pathway and jak/STAT pathway (Huizinga et al., 1995; Ullrich et al., 
1990). The activation of PI3K/Akt pathway may explain in part how activating mutations of 
KIT participate in neoplastic transformation.  
By the induction of cell proliferation and differentiation, KIT is important in erythropoiesis, 
lymphopoiesis, mast cell development and functions, megakaryocytopoiesis, gametogenesis 
and melanogenesis (Rönnstrand, 2004).  
In the absence of SCF, KIT exists in a monomeric dormant state. The mechanism for the 
activation of dormant KIT involves binding of the appropriate ligand to the extracellular 
domain of two receptor monomers; this connection produces a receptor dimer. SCF also 
exists as a non-covalent dimer, which binds to two KIT monomers, thereby promoting KIT 
dimer formation (Zhang et al., 2000). 
In 1988, c-kit gene was founded at the W locus of mouse chromosome 5. The W locus of 
mice encodes KIT. Many types of loss-of-function mutants have been reported at the W 
locus. The W mutant allele is a point mutation at the tyrosine kinase (TK) domain, resulting 
in a dramatic decreasing of TK activity. Heterozygotic W-wild/W-mutated mices show five 
abnormalities due to the loss of KIT function: 1) anemia, due to hypoproduction of 
erytrocytes; 2) white coat colour, due to the lack of melanocytes; 3) sterility, due to the 
depletion of germ cells; 4) depletion of mast cells; 5) depletion of ICCs.  
Molecular analyses of the c-kit gene in W mutants facilitated the understanding of the in 
vivo function of KIT (Hayashi et al., 1991). In 1992, Maeda et al., analyzing c-kit expression 
in phenotipically normal mouse tissues, demonstrated c-kit expression in healthy mouse. 
www.intechopen.com
 
Gastrointestinal Stromal Tumor 
 
4 
Particularly, they showed the presence of KIT-positive cells in GI muscular layers, especially 
in the myenteric plexus layer. Distribution of KIT-positive cells seemed similar to that of 
ICC cells.  
Subsequently, many types of loss-of-function mutant mice have reported at the W locus. 
Myenteric plexus ICCs fail to develop in mice which are deficient in expression of the KIT 
tyrosine kinase receptor or in its ligand SCF, indicating that the KIT-SCF axis is essential for 
the development of these cells. W mutant mice, who had deficiency of KIT-positive cells, 
also had disturbed GI movements, including bile reflux to stomach. These results 
unequivocally demonstrated that ICC are KIT-positive and that pacemaker of GI movement 
is KIT-dependent (Maeda H et al., 1992). Actually, it is well known that loss-of-function 
mutations of KIT also result in mast cells depletion.  
In >80% of GISTs, mutation in the c-kit gene leads to KIT constitutive activation (gain-of-
function mutation). Activating KIT mutations occur in the extracellular, in the 
juxtamembrane and in the proximal and distal protein kinase domains (Table 1), and more 
often consist in single oligonucleotide substitution in exon 11. The penetrance appears to be 
high. 
Since KIT plays an essential role in development of melanocytes and mast cells, most 
individuals with exon 11 mutations may also develop mast cell disease, as well as 
hyperpigmentation of perineal, perioral and digital skin area. This fact does not occur for 
patients with a KIT exon 13 or 17 mutations, suggesting that there are differences in 
signalling requirements for mast cells neoplasia as compared with GISTs. 
 
Tumor type  Location of mutation in KIT 
GIST  Extracellular domain 
Mast cell leukemia  JM segment 
Germ-cell tumor  JM segment 
Mastocytosis  JM segment 
GIST  Proximal kinase domain 
Germ-cell tumor, GIST, mastocytosis  Activation loop 
Germ-cell tumor, GIST  Activation loop 
Seminoma  Activation loop 
T-cell lymphomas  Activation loop 
Table 1. Oncogenic gain-of-function KIT mutations, in human 
The most common mutations in KIT affect the juxtamembrane domain encoding exon 11. 
Two-third of GISTs harbour an inframe deletion, insertion, substitution or combination of 
this exon (Figure 1), while approximately 10% of these neoplasia have a mutation in an 
extracellular domain encoded by exon 9. Rarely, mutations occur in the kinase I (exon 13) 
and kinase II (exon 17) domains.  
In human mast cell leukemia cell line HMC-1, KIT is constitutively phosphorylated in kinase 
domain, activated and then associated with PI3K without the addition of SCF. c-kit gene of 
HMC-1 cells is composed of normal-wild-type allele and of mutant allele having point 
mutations which result in the substitution of Val-560 to Gly in juxtamembrane domain, and 
Asp-816 to Val in tyrosine kinase domain.  
In a transfected cells model, KIT with either mutations is phosphorylated on tyrosine and 
activates without the addition of SCF. The mechanisms of constitutive activation are 
different in the cases of Val to Gly and Asp to Val. A substantial fraction of phosphorylated 
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KIT with Val to Gly mutation dimerizes, whereas phosphorylated KIT with Asp to Val 
mutation does not (Feritsu et al., 1993). 
In general, tumors are heterozygous for a given mutation, but loss of the remaining wild-
type KIT allele occurs in about 8-15% of tumors; in these cases, there would be a strict 
association with a wrong prognosis (Corless & Heinrich, 2008). In a subset of GISTs which 
are wild-type, a high proportion have mutations in either exon 12 or 18 of the plateled-
derived growth factor alpha (PDGFǂ) gene. PDGFǂ substitution in exon 18 is only found in 
GISTs arising in the stomach, mesentery and omentum. 
The importance of KIT mutation in GISTs development is sustained by numerous evidences. 
First, when expressed in transfected cell lines, mutant form of KIT show constitutive kinase 
activity in the absence of SCF (Hirota et al., 1998). Second, mutant KIT is oncogenic (Hirota 
et al., 1998). Third, phosphorylated KIT is detectable in GIST. Fourth, patients with 
hereditary mutations are at high risk for the development of multiple GISTs. Fifth, mice 
engineered to express mutant KIT shows ICC cell hyperplasia and develops stromal tumors 
resembling human GISTs (Rubin et al., 2005).  
4. Interstitial cells of Cajal (ICC) and GISTs 
ICCs were firstly described by Santiago Ramon y Cajal in 1983, as special cells distinct from 
ordinal neurons, forming a network in the GI wall of the Guinea pigs (Cajal, 1983). ICC act 
as the “pacemaker” cell of the gut and serve as intermediaries between the GI autonomic 
nervous system and smooth cells, to regulate GI motility and coordinate peristalsis. 
Although location and density of ICCs vary in different portion of GI tract, the largest 
density of these cells occurs around the myenteric plexus, with extension between 
intramural neurons and smooth muscular cells of the circular and longitudinal layers of the 
muscolaris propria.  
ICCs are classified into several subtypes by anatomical localization; moreover, a subset of 
ICCs are known to mediate neural transmission. In this context, ICCs are considered to play 
different roles. Cajal et al., estimated that ICCs were primitive neurons. Actually it’s well 
known that ICCs would derive from a common precursor that yields ICC and smooth 
muscle cells, but not neurons (Torihashi et al., 1997).  
As previously described, KIT was reported to be expressed by these cells; in fact, ICC 
requires the SCF-KIT system for its development. Loss-of-function mutation of KIT results 
in depletion of ICCs. Conversely, gain-of-function mutation might induce ICCs neoplasms. 
Normal ICCs as well as ICCs neoplasia express CD117. Since leiomyomas and 
schwannomas did not express KIT, but most tumors designated as GISTs did express it, it 
has been postulate the origin of GISTs from ICCs. 
Although more than 90% of GISTs harbour a specific c-kit gene mutation, and approximately 
85% of GISTs have mutations in either KIT or PDGFǂ receptors, recent molecular studies 
defined a subset of gastrointestinal stromal tumors which are clearly KIT- and PDGFRǂ-
negative (kit wild type [kit-WT] (Corless et al., 2002).  
About 12% of the stromal gastrointestinal tumors lack a KIT mutation. Heinrich et al., 
investigating the cause of GISTs without KIT mutation and using Western blotting analysis 
based on a cocktail of antibodies to epitopes pooled by a broad range of tyrosine kinases 
receptors, revealed a gain-of-function mutations of PDGFǂ receptor in about one-third of 
GISTs (Heinrich et al., 2003). Mutated PDGFǂ receptor activates not only itself, but also 
wild-type KIT. Since the signal transduction pathway of PDGFǂ receptor is similar to that of 
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KIT, gain-of-function mutation of PDGFǂ receptor by itself may cause transformation of 
ICCs.  
When compared with kit-positive GISTs, kit-WT tumors are more likely to arise in the 
omentum/peritoneal surface and stomach whereas GISTs kit-positive occurred 
predominantly in the small bowel. The presence of KIT mutation in GISTs has been 
correlated with survival of patients. Survival seems better in patients without KIT mutation 
than in patients without KIT mutation (Taniguchi et al., 1999). Among mutant GISTs, 
comparative studies indicated different pharmacological responsiveness to the kinase 
inhibitor imantinib.  
It is now widely accepted that mutations of other genes are also necessary for GIST to 
emerge from a background of ICC hyperplasia. Particularly, some tumor suppressor genes 
which are closely correlated with tumorigenesis, have been found to harbour abnormalities 
in GISTs. Recently, functional inactivation of p16INK4a gene transcript on 9p21 locus, via 
mutation, deletion, or promoter hypermethylation, causing loss or down-regulation of the 
corresponding protein, has been identified as an independent unfavourable prognostic 
factor in GISTs (Ricci et al., 2004; Sabah et al., 2004; Schneider et al., 2003; Scheneider-Stock 
et al., 2005).  
p16INK4a is one of the two alternative transcripts of the cyclin-dependent kinase inhibitor 2A 
(CDKN2A) gene. The other transcript is p14ARF. The CDKN2A gene, with its two transcripts, 
is an important tumor suppressor gene, with a central role in the control of cell proliferation 
and apoptosis (Sherr, 2001). Haller at al. examined the relevance of the CDKN2A tumor 
suppressor pathway in GISTs and found that the low mRNA expression of the CDKN2A 
transcript p16INK4a, was associated with more aggressive clinical behaviour and adverse 
prognosis (Haller et al., 2005).  
Recently, additional insight on the biology of GISTs has recently been gained through gene 
microarray studies. These studies identified a number of genes whose expression is 
relatively increased if compared to that of other soft tissue tumors. Many genes have not 
been well characterized yet. Among these a GIST-specific gene, encoding for 
FLJ10261protein, has been named “Discovered on GIST 1” (DOG1).  
DOG1 has been recently identified as a gene on human chromosome 11q13, which is 
amplified in esophageal cancer, bladder tumors, and breast cancer. Using 
immunohistochemistry and in situ hybridization technology with DOG1-specific probes, 
West et al., (West et al., 2004) showed DOG1 overexpression in both KIT and PDGFRǂ 
GISTs.  
Because their biological function is still unknown, it is unclear why DOG1 is so widely 
expressed in GISTs. Two possibilities would exist. First, DOG1 might have a role in receptor 
kinase signal transduction pathways; second, it may be a fortuitous marker of the GIST 
phenotype, with no direct connection to the KIT and PDGFRǂ signaling pathways. The 
finding that mast cells are also immunoreactive for DOG1 tends to favour the former 
possibility (West et al., 2004). In this context, DOG1 would be considered a potential 
alternative therapeutic target.  
p27 cell cycle inhibitor seems to be downregulated in malignant GISTs; cycle regulatory 
proteins (cyclins B1, D and E, cdc2, CDK2, CDK4 and CDK6), p53, pRb and cyclinA have 
been found to be upregulated in high-risk GISTs. The above mentioned molecules have been 
proposed as immunohistochemical target of high-risk gastrointestinal stromal tumors 
molecular (Romeo et al., 2009).  
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In addition to the above mentioned markers, an increasing list of prognostic factors have 
been reported: Ezrin, Raf kinase inhibitor protein, COX-2, bcl-2, CA II (Romeo et al. 2009). 
However standardized protocols for interpretation of these markers have not been establish 
yet.  
5. GISTs epidemiology and clinical presentation  
Mesenchymal tumors of GI tract are divided into two main groups: 1) tumors which are 
histological identical to thei soft tissue counterpart (e.g., lipomas, leiomyiomas etc.); 2) 
gastrointestinal stromal tumors, which represent approximatively 1% of all primitive 
tumors, 0.1-3% of all gastrointestinal neoplasia and are, at the same time, the most frequent 
mesenchimal lesions of gastrointestinal tract. GISTs have distinctive histologic and clinical 
features that vary according to their primary site of origin. 
The exact incidence of GIST in USA and in Europe is hard to determine, since GISTs have 
only been recognized and diagnosed as a separate entity since the late 1990s. Recent 
population-based studies performed in Sweden (Nilsson et al., 2005), Holland (Goettsch et 
al., 2005) found incidences of approximately 14.5 and 12.7 cases/million/year, respectively. 
These findings would translate into an annual incidence in Europe of about 8,000-9,000 cases 
and in USA of about 5,000 new cases per year. They are frankly malignant in 10-30% of cases 
and are responsible for cancer mortality in 2% of cases. Sporadic GIST has no clear gender 
preference; at the time of diagnosis, the majority of patients with GISTs are between 40 and 
80 years old, with a median age of 60 years.  
GISTs can develop in any part of the digestive system, from the oesophagus to the rectus. 
They arise predominantly in the stomach (60%), jejunum and ileum (30%), duodenum (5%), 
and colon-rectum (<5%). Very few cases have been described in the oesophagus and 
appendix (<5%) (Miettinen et al., 2006). Tumor lacking any association with the bowel wall 
(omental, retroperitoneal and mesenteric localizations) are known as Extra Gastrointestinal 
Stromal Tumor (EGIST). Mesentery or omentum lack the ICCs; this fact confirms GIST’s 
origin from these cells.  
Most gastrointestinal stromal tumors occur sporadically, and present themselves as solitary 
lesions.  
GISTs have a predominant exophytic growth, along the gastrointestinal tract and frequently 
protrude into the abdominal cavity. In smaller neoplasia, the mucous membrane is 
frequently intact, and the muscle layer of the mucosa seems to be coalescent with the 
muscular layer; in other cases, tumor may compresses the muscular layer, from which it is 
delimited by a thicker collagen band. Ulceration of mucous membrane may occur but in 
case of large, aggressive tumors.  
Commonly, the tumors are well delimited, not encapsulated, firm in consistency, whitish. 
Macroscopically, GISTs present most often as a well-circumscribed and highly vascular 
tumors. On gross examination, these tumors appears fleshy pink or tan-white and may 
show hemorrhagic foci, central cystic degenerative changes, or necrosis. Invasion of the 
adjacent organs can occurs in one-third of cases (Figure 3).  
Due to their submucosal or intramural location, small GISTs come often incidentally evident 
during radiological procedures, surgical intervention for other pathologies or autoptic 
examination. On the other hand, patients with malignant GIST often present with 
disseminated disease. 
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Fig. 3. Commonest macroscopic appearance of gastrointestinal stromal tumor. gelatinous cut 
surface with focal haemorrhagic foci, central cystic degenerative changes and/or necrosis  
The presenting manifestations of gastrointestinal stromal tumors depend on the GI site of 
origin, the precise portion of the gut wall in which the tumor is located and the size of the 
neoplasia. A significant number of benign, small tumors are asymptomatic and are 
accidentally found. In larger tumors, clinical symptoms include abdominal pain, fatigue, 
dysphagia, satiety and obstruction. Patients may present with chronic acute GI bleeding 
(causing anemia), acute GI bleeding (caused by erosion through the gastric or the bowel 
mucosa), or rupture into the abdominal cavity causing intraperitoneal hemorrhage. In 
general, about 70% of GISTs are associated with clinical symptoms, 20% are not, and 10% 
are detected at autopsy (Nilsson et al., 2005). The median tumor size in each of the previous 
categories is 8.9, 2.7 and 3.4 cm, respectively (Nilsson et al., 2005).  
In general, tumors infiltrating the mucosa are virtually always malignant. Radiologic 
imaging studies, including barium contrast, computer tomography and endoscopic 
ultrasound, are commonly used for the diagnosis and the evaluation of these neoplasms. In 
addition, some tumors can be diagnosed by cytology, although separation of benign and 
malignant GISTs is usually not always possible. 
GIST metastasis have been reported in 50% of patients. They can quite often occur 10-15 
years after initial surgery; therefore, long-term follow-up is required. Metastases develop 
primarily in the abdominal cavity and liver, exceptionally in lymph nodes or in the lung (De 
Matteo et al., 2000). 
Most of GISTs of omentum, mesenteries, and retroperitoneum are metastatic from the GI-
tract (Tsukuda et al., 2007); in these cases, peritoneal involvement with ascites may be the 
sole presenting features of these tumors.  
Histopathologic examination of surgical resection specimens represents the most common 
method in GIST diagnosis.  
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6. Familial, paediatric and multiple GISTs 
Although the majority of gastrointestinal stromal tumors present as sporadic and solitary 
gastrointestinal mass in adults aging 50-70 years, with no associated risk factors, a small 
subset of GISTs (about 5%) occur in the setting of familial or idiopathic multitumor 
syndrome (neurofibromatosis type 1-NF1-, Carney triad and familial GIST syndrome), in 
with heritable mutations in KIT or PDGFRǂ receptors have also been identified (Table 1).  
Patients with NF1 have an up to 180-fold increased risk for GISTs, compared with the 
general population. The majority of NF1 GISTs arise in the small bowel, often in a multifocal 
appearance. In this context, distinguishing patients with NF1 and multiple GISTs from those 
having sporadic GISTs with multiple metastasis is often essential. Most of NF1 
gastrointestinal stromal tumors are small, cytologically bland, mitotically inactive and 
follow and indolent course. Then the suspicious for NF1 should be high when multiple, 
small intestinal GISTs are encountered. Diffuse hyperplasia of ICCs is often seen in the 
myenteric plexus adjacent to neoplastic masses. 
The pathogenesis of NF1 GISTs appears to be different from that of sporadic tumors since it 
has been demonstrated a very low frequency of associated KIT and PDGFRǂ mutations 
(Ponti et al., 2011).  
Paediatric GISTs are considered a separate clinicopathologic entity and occur predominantly 
in the second decade (Juneway et al., 2007). In paediatric and adolescents, gastrointestinal 
stromal tumors account for 1-2% of all GISTs (Fletcher et al., 2002).  
Molecular analyses detect KIT/PDGFRǂ mutations in a small percentage of cases of 
paediatric GI stromal neoplasia (10-15%) (Antonescu et al., 2006; Fletcher et al, 2002). 
Paediatric GISTs are more prevalent in females (female/male ratio: 9:1), occur preferentially 
in the stomach (88%), display epithelioid or mixed cell morphology (82%), lack of ICC 
hyperplasia (100%), are slow to progress but can metastasize with a worse prognosis. Unlike 
adult GISTs, these tumors commonly involve local lymph nodes Prakash et al., 2005). By 
contrast, paediatric GISTs with KIT or PDGFRǂ mutations have very different features: 
prevalence is greater in males, lesions tend to be unifocal and usually occur in extragastric 
locations, and spindle-cell morphology is found in all cases (Agaram et al., 2008; Janeway et 
al., 2007); in other words, they share many of the features of spontaneous adult tumors.  
Paediatric gastric GISTs are sometimes associated with pulmonary condromas or 
paragangliomas, referred to as Carney triad (CT) (Carney, 1999). A number of other lesions 
have been described in the condition also including pheochromocytomas, oesophageal 
leiomyomas and adrenocortical adenomas. CT is now considered a novel form of multiple 
endocrine neopasia (MEN), a genetic condition with a female predilection. Stratakis et al., 
recently reported a deletion within the 1pcen13-q21 region, which harbours the SDHC gene. 
Another frequent change was the loss of 1p. although GISTs showed more frequent losses of 
1p than paragangliomas, the pattern of chromosomal changes was similar in the two 
tumors, despite their different tissue origin and histology. These findings are consistent with 
a common genetic aetiology.  
Another separate condition in which the dyad GISTs/paragangliomas is inherited is 
Carney-Stratakis syndrome (CSS); here germline mutation of SDHB, SDHC and SDHD 
genes (but not KIT or PDGFRǂ) has been found.  
In very rare case, GISTs may be detected in many organs (multiple GISTs). However, this is 
not necessarily an indicator of greater aggressiveness. In general, multiple sporadic GISTs 
are associated to familial GIST syndrome, to Carney triad or Carney-Stratakis syndrome. In 
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many cases of multiple GISTs, prognosis and treatment differ from those of conventional 
GISTs. In these circumstances differential diagnosis is mainly based on clinical and genetic 
studies, rather than on morphological, immunohistochemical or molecular analyses.  
7. Pathology 
Morphologic evaluation reveals three principal subtypes of GIST, depending on the 
cytomorphology. Most GISTs (about 70% of cases) are comprised of a fairly uniform 
population of spindle cells, arranged in a short fascicles or whorls; cytoplasm is sparse, 
fibrillary, basophilic or rarely eosinophilic, and sometimes contain PAS positive juxtanuclear 
vacuoles. The nuclei are monomorphous, flattened, have blunt ends and are bullet or cigar 
shaped; however, they can also be long and pointed. Nuclear pleomorphism is not 
characteristic for GISTs. The tumor may exhibit a storiform, pallisading or herringbone 
pattern; in this cases GISTs can simulate smooth muscle tumors or tumors of the neural 
sheet (Figure 4). Larger tumors may present calcification zones. 
 
 
Fig. 4. Spindle cells GIST variant. Ematoxinin-Eosin staining, 20X magnification  
(from GIST Support International - Pathology Analyses for GIST at www.gistsupport.org). 
About 20% of GISTs are dominated by epithelioid round cells, with eosinophilic to clear 
abundant cytoplasm, and arranged in sheets and nests (Figure 5). This microscopic form can 
be particularly found in gastric tumors, showing round or eccentric nuclei, with perinuclear 
vacuolization and small nucleoli. Scattered multinucleated giant cells or cells with bizarre 
nuclei can be present. Mitotic figures are rare. Collections of extracellular collagen, called 
skeinoid fibers, may be seen in either spindle and epithelioid variants.  
In general, most epithelioid GISTs arising in the stomach are benign, in contrast with those 
of small intestine, where the prominent epithelioid component is often malignant (Miettinen 
et al., 2005).  
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Fig. 5. Epitheliod cells GIST variant. Haematoxinin-Eosin staining, 40X magnification  
Approximately 9% of gastrointestinal stromal tumors show mixed morphology, being 
composed of both spindle and epithelioid cells (biphasic GIST). Variable cellularity as well 
as sclerotic, collagenous or myxoid stromal changes can be seen. Spindle cells usually can 
show nuclear palisading or storiform growth pattern, resembling that of peripheral 
schawannomas; in these cases prominent perinuclear vacuolization is a typical feature.  
Overall, GISTs are considered as uniform and monotonous tumors. Pleomorphic and 
dedifferentiated GISTs are occasionally seen. Mitotic activity is generally low. 
Rarely, GISTs may also show signet ring cell features and oncocytic variant. The first variant 
frequently affect women, and present itself as a small, well circumscribed nodule, 
histologically characterized by a proliferation of large, round to oval cells containing 
abundant clear cytoplasm and with nuclear displacement toward the cellular periphery. The 
second histological variant is characterized by an abundance of mitochondria and by 
eosinophilic cytoplasm.  
Gastrointestinal autonomic nerve tumor (GANT) is also considered a GIST variant. GANT 
main localization is the small intestine, rarely the stomach, occasionally the large intestine, 
the oesophagus, the retroperitoneum and the mesentery. It affects mainly the male 
population aged over 60 years. Tumors occurring in younger person and with gastric 
localization usually accompany the Carney triad. Microscopically, GANTs are similar to 
other stromal tumors (epithelial or spindle shape with myxoid stroma). The presence of 
skeinoid fibers is more frequently observed than in other stromal tumors; lymphoid 
aggregates can be frequently seen around the tumoral cell nests, but malignant potential is 
not different from that of GISTs with the same size, histological features and localization. 
Although a lot of information has been reported about the histological pattern of GISTs, 
little is still known about the cytologic appearance of gastrointestinal stromal tumors, 
particularly in effusions. 
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In ascitic fluid, GISTs morphologically resemble adenocarcinomas (Figure 6). The most 
confusing findings are related to cells in a nested pattern and to the occurrence of prominent 
intracytoplasmic vacuoles (Figure 7). In these case, it would be essential the 
immunocytochemical study of the neoplasia.  
 
 
Fig. 6. Morphologic appearance of gastric GIST in ascetic fluid: 3-dimensional sheets of cells 
with a gland-like prevalent pattern. Papanicolaou stain, 40X magnification  
 
 
Fig. 7. Gastric GIST in ascetic fluid: tumor cells show epithelioid appearance with high 
nuclear/cytoplasmic ratio, prominent nucleoli and intracytoplasmic PAS-negative vacuoles, 
PAS stain, 63X magnification (from Zappacosta et al., (2009) Thin-Layer Cytopathology of a 
Gastrointestinal Stromal Tumor (GIST) in Effusion: Diagnostic Dilemmas. Annals of Clinical 
& Laboratory Science, 39; 4:367-371)  
www.intechopen.com
 
GISTs: From the History to the Tailored Therapy 
 
13 
8. Morphologic risk assessment in GISTs 
Although the vast majority of GISTs smaller than 2 cm are clinically benign lesions, 
occasionally patients will develop metastasis, sometimes 5 years or more after primary 
excision. Therefore, the older classification that used the terminology “benign” or 
“malignant” GIST have been replaced by stratification schemes which help in predicting the 
risk of aggressive clinical behaviour. 
The first widely accepted scheme was published in 2002 by Fletcher et al., after a consensus 
workshop held at the National Institutes of Health (Fletcher et al., 2002). In this scheme, risk 
assessment is based on tumor size and mitotic activity (per 50 high power fields – HPF). The 
most important cut-offs as indicator of aggressive clinical behaviour is tumor size of 5 cm 
and 5 mitoses/50 HPF. According to this 2002 consensus guidelines, all GISTs may have 
malignant potential. In 2005 and 2006, Miettinen et al., from the AFIP presented two very 
massive studies of gastric and jejunal/ileal GISTs, providing strong evidence that tumor 
located in the stomach have a much lower rate of aggressive behaviour that of jejunal and 
ileal, having similar size and mitotic activity (Miettinen et al., 2006). Basing on these 
publications, anatomic location is now included as an additional parameter in risk 
assessment for GIST, together with nodular size and mitotic count (Table 2). To date, 
tumoral location outside of the stomach seems to be a prognostic factor for survival 
independent of the mitotic count and tumor size.  
Of interest is the prognostic nomogram that could be drawn after the complete surgical 
resection of primary GISTs; basing on GIST size, mitotic index and site parameters, it would 
be useful in predicting the probability of 2- and 5-years recurrence free survival (Gold et al, 
2009), and in stratifying patients for adjuvant pharmacological treatment. 
 
Mitotic index (number of  
mitosis/50 HPF) 
Size (cm) 
Risk of progressive disease  
in Gastric, duodenal,  
small intestinal  
and rectal localization 
≤5 ≤2 None in all 
≤5 >2≤5  Very low, low, low, low 
≤5 >5≤10 Low, not reported, moderate,  
not reported 
≤5 >10 Moderate, high, high, high 
>5 ≤2 None, nor reported, high, high 
>5 >2≤5 Moderate, high, high, high 
>5 >5≤10 High, nor reported, high, not reported 
>5 >10 High in all 
Table 2. Risk stratification of primary GIST.  
8.1 Gastric GISTs 
These neoplasia can be divided into four main types: benign and malignant spindle cell 
tumors (Figure 3) and benign and malignant epithelioid tumors (Figure 4). These tumor 
types can usually be distinguished by the assessment of a combination of histologic features 
(Tables 3 and 4) 
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ELEMENTS BENIGN MALIGNANT 
Cellularity high high 
Mitotic figures <2/50 HPF Usually >5/50 HPF 
Perinuclear vacuoles present usually absent 
Nuclear atypia often absent Present 
*HPF, high power field 
Table 3. Histologic characteristics of benign and malignant spindle shape gastric GIST 
 
ELEMENTS BENIGN MALIGNANT 
Cellularity low high 
Mitotic figures <2/50 HPF Usually >5/50 HPF 
Nuclear atypia often absent usually present 
Necrosis often absent usually present 
Table 4. Histologic characteristics of benign and malignant epithelioid gastric GIST  
8.2 Small bowel GISTs 
The small bowel represents the second most common site of gastrointestinal stromal tumors. 
Unlike GISTs of the stomach, those that occur in the small gut are usually composed of 
spindle cells. usually, epithelioid variants are rare. The spectrum of histologic feature is 
completely different from that of gastric localization (Table 5). In general, more small bowel 
GISTs are malignant than gastric tumors.  
 
ELEMENTS BENIGN MALIGNANT 
Cellularity low high 
Mitotic figures <5/50 HPF >5/50 HPF 
Nuclear atypia low high 
Necrosis absent often present 
Table 5. Histologic characteristics of small bowel stromal tumors  
8.3 Colonic GISTs 
The colon represents the least common site of these neoplasia. Histologically, benign 
stromal tumors of the colon are rare. Colonic GISTs are more heterogeneous than those of 
other sites and include highly cellular spindle cell tumors and highly pleomorphic 
sarcomas. Most patients present metastases at the time of clinical presentation and show 
poor survival (Miettinen at al., 2009). Tworek et al., showed that an infiltrative growth 
pattern in the muscolaris propria, mucosal invasion and high mitotic counts (>5/50 HPF) 
correlated significantly with metastasis and deaths Tworek et al., 1999). On the other hand, 
coagulative necrosis and dense cellularity were found to be minor criteria in the prediction 
of adverse outcome (Table 6) 
 
ELEMENTS Low-risk GISTs High-risk GISTs 
Cellularity low usually high 
Mitotic figures ≤5/50 HPF >5/50 HPF 
necrosis absent usually present 
Table 6. Histologic characteristics of low-risk and high-risk colonic GISTs  
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8.4 Anorectal GISTs 
The most common mesenchymal tumor of this site is leiomyoma. This lesion is composed of 
differentiated benign smooth muscular cells derived from the muscolaris mucosae and is 
usually cured by local excision. Apart leiomyoma, most mesenchymal tumors of the 
anorectum are spindle cell neoplasia, having similar light microscopy, 
immunohistochemical and molecular genetic alterations of those of GISTs arising in other 
parts of GI tract. All anorectal GISTs are malignant, regardless their histologic appearance. 
Hovewer, several recent studies have showed the contrary. As with GISTs which develop in 
other sites, a wide range of features can be used to separate benign from malignant 
behaviour (Table 7).  
 
ELEMENTS Low-risk GISTs High-risk GISTs 
Tumor size <2 cm >5 cm 
Cellularity low usually high 
Mitotic figures ≤5/50 HPF >5/50 HPF 
Table 7. Histologic characteristics of low-risk and high-risk GISTs 
The most common form of anorectal GIST develops in the muscolaris propria and is 
characterized by fascicles of densely cellular, spindle shaped cells with elongated and 
uniform nuclei, often showing prominent nuclear palisading. Unlike gastric GISTs, anorectal 
tumors rarely show predominant epithelioid morphology. Malignant tumors tend to be 
located in the muscolaris propria and show mild nuclear atypia and high mitotic counts. 
Tworek et al., demonstrated that tumor size larger than 5 cm and an infiltrative growth 
pattern within muscolaris propria, correlates with an adverse outcome (Tworek et al., 1999). 
On the contrary, nuclear plemorphism, necrosis, mitotic counts and intramuscular 
localization did not correlate with clinical behaviour. This studies also revealed a long 
latency period before recurrence and metastasis, thus emphasizing the need for long-term 
follow-up in patients with these tumors  
8.5 Oesophageal GISTs 
Benign leiomyiomas represents the most common type of mesenchymal tumor also in this 
site, while oesophageal GISTs are rare. These last usually have a male predilection, more 
often present with dysphagia, and typically arise in the distal oesophagus, often involving 
esophagogastric junction. Grossly the have a soft consistency, with a fleshy, variegated cut 
surface, frequently with central necrosis and cystic changes.  
histologically, they are typically high cellular spindle shaped neoplasms, composed of 
mildly atypical nuclei and a wide range of mitotic activity. A variety of morphologic 
patterns may be seen, including sheets of cells, with or without nuclear palisading, 
myxoid change, and hyaline-like degeneration. coagulative necrosis and mucosal invasion 
are rare. 
9. Immunohistochemistry of GISTs 
9.1 c-kit and PDGFRα antibodies 
The key features of GISTs is the positivity for the KIT (CD117) receptor tyrosine kinas (c-kit), 
observed in more than 95% of the tumors. c-kit is considered a marker with high levels of 
sensitivity. However, although c-kit positivity is a major defining features for GIST, it 
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should not be considered an absolute requirement. It is very important to point out that c-kit 
expression in GIST is a constitutional feature and not a consequence of mutation. 
CD117 GIST positivity is often pancytoplasmic. Membrane staining is also observed in 
epithelioid variants (Figure 8).  
 
 
Fig. 8. CD117 GIST positivity. 20X magnification  
The intensity of c-kit immunostain is variable. In most cases it is weakly and not 
homogeneous. In other cases, only a small percentage (10-20%) cells shows CD117 
positivity. The minimum percentage of CD117-positive tumoral cells needed to establish 
GIST diagnosis has been not established yet but if this percentage is below 10% and positive 
cells are isolated or arranged in small groups it is important to differentiate them from mast 
cells. 
There are some rare cases of negative c-kit GISTs (about 5%). In these cases, diagnosis of 
GIST should be cautious and should be made only after the elimination of some cases that 
might determined the marker negativity, such as possible technical errors. Specific kit 
antibodies should react with normal KIT-positive components, such as mast cells and ICC 
and not with normal smooth muscle cells or fibroblasts. CD117 could also tested negative in 
GISTs previously treated with imatinib, and in metastatic or congenital lesions. In these 
cases, a molecular study o KIT or PDGFRǂ mutations would be essential.  
Basing on the above considerations, it is possible to assert that CD117 is not specific for 
GISTs. This marker is also expressed, in seminoma, melanoma, follicular thyroid carcinoma, 
small cells lung carcinoma, thymic carcinoma and thymomas, angiosarcomas, chronic 
myeloid leukemia, mast- cell tumors, germinal tumors etc. Fortunately, the distinction 
between GISTs and these other tumors can be easily made with histological observation and 
with the use of other more specific markers. 
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PDGFRǂ strong immunopositivity is often observed in PDGFRǂ mutated GISTs. However, 
these finding needs further evaluation. 
9.2 CD34 antibody 
CD34 is less sensitive than CD117 and is expressed in 60-70% of tumors localized in 
oesophagus, rectum, and rarely in small bowel. CD34 is a hematopoietic progenitor cell 
antigen also expressed in endothelial cells, subsets of fibroblasts and in tumors related to 
these cell types. CD34 expression does not seem to have a significant prognostic factor. 
9.3 Muscle cell markers 
Approximately 30% of GISTs, more often located in small intestine, are positive for smooth 
muscle actin (SMA), whose expression is sometimes reciprocal with that of CD34. SMA 
positivity may be focal or extensive.  
Often, when normal smooth muscle fibers infiltrate GIST cells, the result is the presence of 
SMA (and Desmin) positive spindle cells within stromal stromal neoplasia; this 
“contamination” should not be confused with GIST SMA-positivity; in fact GIST SMA-
positivity has been statistically correlated with favourable prognosis in gastric and intestinal 
neoplasia (Miettinen et al., 2006).  
Desmin positivity is rare in GISTs of all sites, If positive to desmin, GISTs have gastric 
localization and are of epithelioid variant. It is important to note that imatinib treatment 
may induce desmin expression. 
H-caldesmon it has been recently introduced among the diagnostic immunohistochemical 
panel for GISTs. It is a protein associated with actin, and is expressed in normal and 
neoplastic smooth muscle cells such as leiomyomas and leiomyosarcoma. The association of 
positivity for h-caldesmon, SMA and desmin would guide the diagnosis towards a smooth 
muscle tumor rather than towards a GIST. 
9.4 Neural markers 
S100 protein expression is rare in GISTs, but seems to be more common in neoplasia of small 
bowel than in that of stomach. In this context, S100 protein positivity seems to be an adverse 
prognostic factor in gastric but not in small intestinal GIST (Miettinen et al., 2006).  
GISTs are also positive for nestin, a type VI intermediate filament protein that is typical of 
many stem cells, including those of nervous and muscular systems. Nestin is also present in 
GI schwannomas, this suggesting a relative low specificity for GIST diagnosis.  
Gastrointestinal stromal tumors are positive for vimentin and negative for glial fibrillary 
acid protein (GFAP). This negativity helps to distinguish GISTs from GI schwannomas, that 
test GFAP positive. 
Cytokeratin positivity can be also seen in GIST, especially CK18 and CK8, but not CK19 and 
CK20. Antibodies cocktails such as AE1/AE3 would usually give negative results.  
9.5 DOG1 
It has been recently realized that DOG1 is the same protein called anoctamin I or 
TMEM16A, known to act as calcium-activated chloride channel (Gomes-Pinilla et al., 2009).  
DOG1 expression has been described in a large series of normal cell types, including ICCs, 
myoepithelial/basal cells in breast and prostate etc. The pattern of positivity is essentially 
cytoplasmic and/or membranous. DOG1 is now considered a higher sensitive marker of 
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GIST than CD117; about one-third of c-kit negative GISTs shows DOG1 positivity (Liegh et 
al., 2009) even if a small minority (at least, 1%) may be both CD117 and DOG1 negative. 
It has been noted that only four GIST mimics potentially express both CD117 and DOG1: 
angiosarcomas, synovial sarcomas, Ewing’s sarcomas and melanomas. In the above 
mentioned neoplasia, immunostaining for either markers is focal, whereas in GISTs is 
diffuse. It has been proposed that in histologically suspected GIST and in presence of diffuse 
c-kit and DOG1 immunopositivity, no other immunohistochemical testing would be 
required.  
It should be take in consideration that: (i) gastrointestinal leiomyomas may shows some 
DOG1-positive ICCs intermingled with neoplastic smooth cells; the presence of these cells 
within leiomyomas raises the question if these tumors are effectively true neoplasia or, 
instead, nodular hyperplasia. (ii) A number of carcinomas may occasionally tested positive 
for DOG1; some of these neoplasia, especially adenocarcinoma, may also tested CD117-
positive (West et al., 2004). 
9.6 Immunocytochemical markers 
As previously described, in effusions GIST cells may be acquire an epithelioid appearance 
characterized by nested pattern and prominent intracytoplasmic vacuoles. In order to 
differentiate GIST from other epithelioid and non-epitheliod neoplasms, the 
immunocytochemical assessment of the tumor would be imperative. Positive 
immunoreactivity for vimentin, but not for cytokeratins, within gland-like structures would 
suggest the mesenchymal nature of the tumor; PAS-negativity demonstrating the lack of 
mucin within cytoplasmic vacuoles can also supported the diagnosis of GIST.  
10. Differential diagnosis 
Obviously, differential diagnosis has been very much facilitated by immunohistochemistry, 
using a complete and specific panel of antibodies for mesenchymal tumors. Neoplasia with 
smooth muscle differentiation (leiomyiomas and leiomyosarcomas, SMA+, desmin+ but 
CD117- and CD34-negative) will be taken into account. Differential diagnosis also includes 
tumors with nervous differentiation, such as gastric schwannomas (S100+, CD117-), tumors 
with fibrous differentiation, such as fibromatosis (CD117-), inflammatory gastric polyps and 
inflammatory myofibroblastic pseudo-tumor CD117- and CD34-).  
Histological pattern would exclude retroperitoneal undifferentiated liposarcomas, as well as 
two CD117-positive mesenchymal tumors: metastasis of malignant melanomas and 
angiosarcoma. 
In effusion, GIST should be distinguished from mesotheliomas and amelanotic melanomas. 
Mesotheliomas may display PAS-negative, or rarely PAS-positive, intracytoplasmic 
vacuoles but, in contrast with GISTs, it shows pancytokeratin positivity. Amelanotic 
melanomas may show a weak CD117-positivity, as well as vimentin-positivity; however, 
melanomas cells usually grow as single elements and stain S100-positive, whereas GIST cells 
aggregate in three-dimensional clusters usually staining S100-negative. 
11. GISTs surgical approach 
Complete surgical resection with microscopically negative margins represents the standard 
of care for patients presenting primary resectable GISTs. Particularly, neo-adjuvant therapy 
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for those with resectable disease is actually not recommended, although preoperative drug 
administration may be considered for patients with marginally resectable tumors and for 
those having potentially resectable disease but at increased risk of significant morbidity. 
11.1 Lesions smaller than 2 cm 
When small oesophageal, gastric or duodenal nodule less than 2 cm in size are detected, 
endoscopic biopsy may be difficult; in these cases, laparoscopic or laparotomic excision may 
be elective in order to achieve a histological diagnosis. According to the new guidelines, 
GISTs smaller than 2 cm must to be regarded as essentially benign. For this reason, the 
standard approach to these patients relies on endoscopic ultrasound assessment and then 
follow-up. Excision would then reserved for patients whose tumor increases in size or 
becomes symptomatic. For rectal tumor, the standard approach is biopsy/excision after 
ultrasound assessment, regardless of tumor size, because the risk of GIST at this site is high.  
11.2 Lesions larger than 2 cm 
In this case, the standard approach is biopsy/excision. In presence of larger mass, especially 
if surgery might imply multivisceral resection, multiple core needle biopsies represent the 
standard approach. Obviously, accurate assessment of the histotype is essential.  
12. Molecular target therapy 
Because constitutive activation of KIT and PDGFRǂ has been demonstrated in GIST 
development, the inhibition of these activated kinases has been verified to be effective for 
the treatment of this neoplasia. 
Imatinib is an orally bioavailable 2-phenylaminopyrimidine derivative, developed in 1990s 
as a treatment for myelogenous leukemia. Imatinib shuts off oncogenic signalling from the 
fusion oncogene Bcr-Abl in chronic myelogenous leukemia cells by occupying the ATP-
binding pocket of the Abl kinase domain. Abl shares considerable homology with the type 
III receptor tyrosine kinase family (Reichardt et al., 2011). In addition to the inhibitory effect 
of imatinib mesylate on PDGFRǂ and Bcr-ABL, it has been found an inhibitory effect on 
wild-type KIT (Reichardt et al., 2011). The fist GIST patient successfully treated with 
imatinib was reported in 2001 (Druker et al., 2001). Subsequently, a multicenter trial on 
advanced GIST was done in 2002 and significantly effect was reported (van Oosterom et al., 
2002). Consequently, FDA approved imatinib mesylate as an effective therapeutic agent for 
patients with metastatic or un-resectable KIT-positive GIST. Obviously, an accurate 
pathological diagnosis of GIST condition by using immunohistochemistry for KIT is 
necessary. 
Imatinib reliably achieves disease control in 70-85% of patients with advanced GISTs, with a 
median progression-free survival of 20-24 months. The estimated median overall survival 
time following imatinib therapy exceeds 36 months (Corless et al., 2008).  
As previously described, imatinib is effective in the majority of GIST patients, but tumor 
regrowth by resistant clones occurs during continuous therapy (secondary resistance) 
(Joensuu et al., 2008). The main cause of this event seems to be a second mutation in the 
same genes. For these reasons, several new drugs for GIST including the imatinib-resistant 
are under development or clinical trials. 
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12.1 Therapy for localised resectable disease 
Estimation of recurrence risk of GIST after resection is very important during the selection 
of patients for adjuvant imatinib. 
Size, mitotic count and anatomic localization have been widely accepted as predictive of 
outcome, but tumor rupture, incomplete resection and c-kit/PDGFRǂ mutational status also 
impact on disease-free survival (Joensuu et al., 2008). Particularly, when compared with 
exon 11 mutants, the presence of exon 9 mutations and wild-type GIST were the strongest 
adverse prognostic factors for response, risk of progression and death (Dematteo et al., 
2009).  
Questions remain regarding post-operative or adjuvant therapy. The American College of 
Surgeons Oncology Group conducted a randomised, phase III trial of adjuvant imatinib 
after surgical resection of primary GIST. They randomly assigned 713 adults with a 
completely resected GIST ≥3 cm in size and immunohistochemically positive for KIT to 1 
year of adjuvant imatinib or placebo. At a median follow-up of 20 months, 30 patients in 
the imatinib group had recurred or died, versus 70 given placebo. The 1-year recurrence 
free-survival was 98% versus 83%, favouring imatinib (Dematteo et al., 2009). basing of 
these findings, FDA approved the use of imatinib for patients having completely resected 
GIST ≥3 cm in size. However, the optimal duration of therapy for patients remains 
unclear. Actually two additional European trials have been completed: EORTC  
62024 randomized trial assessing the overall survival of patients with intermediate and 
high-risk GIST after 2 years of imatinib or observation alone; Scandinavian Sarcoma 
Group trial XVIII, that evaluated recurrence-free survival of patients with high-risk 
disease after 1-3 years of adjuvant imatinib. Data from there trials are shortly to be 
published.  
12.2 Therapy for un-resectable or metastatic disease 
Systemic chemotherapy for advanced GIST is highly ineffective: response rate is less than 
10% (Dematteo et al., 2002). Imatinib blocks KIT/PDGFRǂ signalling by binding to the ATP-
binding pocker required for phosphorylation and activation of the receptor. In vitro data 
demonstrated that imatinib leads to the interruption of cell proliferation through the 
inhibition of downstream phosphorylation.  
12.3 Management of refractory GISTs 
The median time to progression on first-line imatinib is about 2-2.5 years. Dose escalation 
should be considered in patients who had imatinib therapy but shows clear evidence of 
progression. The efficacy of this approach was demonstrated in the European dose-finding 
study (Zalcberg et al., 2005).  
Sunitinib, nilotinib and dasatinib represent the second generation of multitargeted tyrosine 
kinase inhibitors. The role of this new pharmacological approach to GIST was established by 
an international phase III trial performed on patients intolerant to or with imatinib-resistant 
GIST. this trial revealed highly statistically significant benefits in terms of response rate, 
time of progression and overall survival.  
Sorafenib, is a multitargeted tyrosine kinase inhibitor with potent activity against B-RAF 
tyrosine kinase, VEGFR, PDGFR, KIT and FLT3. has been investigated in a phase II study 
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involving patients with imatinib- and sunitinib-resistant GIST. This trial demonstrated an 
overall progression free survival of about 22 months (Wiebe et al., 2008).  
Heat shock proteins (HSP) help to maintain malignant pathway buy stabilizing mutated 
proteins. Inhibition of HSP 90 destroys the activated KIT/ PDGFRǂ, potentially leading to a 
therapeutic effect in GIST patients. However, an international phase III trial in patients with 
metastatic and/or un-resectable neoplasia after failure of imatinib and sunitinib 
demonstrated higher mortality rate among patients in the treatment arm. 
Flavopiridol is an inhibitor of cyclin-dependent kinase (CDK1 and CDK2). In preclinical 
studies, this molecule induced a high level of apoptosis in GIST cells, at clinical doses.  
Although a wide range of studies has been done about GISTs pharmacological therapy, 
many questions remain controversial. For these reasons, currently sunitinib represents the 
only standard targeted therapy available in imatinib-refractory GISTs. For this reason, an 
urgent need for new drugs exist. However, due to the relatively rarity of GIST disease,  
it is may difficult to accumulate an adequate number of patients for clinical trials. Basing 
on these considerations, collaborations among medical centers worldwide would be 
crucial.  
13. Mutational analyses to predict GISTs pharmacological response 
It has been reported that also the location of KIT and PDGFRǂ mutations is related to 
pharmacological response to imatinib (Wardelmann et al., 2007). Then, assessing the 
presence and the type of GIST mutation can help to predict response to pharmacological 
therapy. Particularly, GIST with JM domain mutations of the PDGFRǂ appeared to respond 
to imatinib but GIST with TK domain mutation of the same gene, as well as GIST without 
any detectable c-kit or PDGFRǂ mutations did not. Moreover, pharmacological response to 
imatinib was higher for GIST with mutations with JM domain of c-kit gene than that of GIST 
with EC domain mutation of the same gene (Debiec-Rychter et al., 2006)..  
The genotype profile associated with primary resistance to sunitinib is just the opposite of 
that of imatinib: KIT exon 9 mutetions and wild-type genotype predict for a better response 
that exon 11 mutations (Heinrich et al., 2008). Mutations predicting primary resistance to 
both imatinib and sunitinib, such as PDGFRǂ exon 18 mutation (D842V), also exist (Corless 
et al., 2005; Prenen et al., 2006).  
In a majority of cases, secondary resistance to imatinib is due to prolonged exposure to the 
drug, which induces the emergence of GIST cell clones, bearing additional, resistance-
mediating mutations (Liegl et al., 2008; Wardelmann et al., 2006). The vast majority of these 
so-called secondary mutations causing imatinib resistance have been found in KIT exons 13, 
14, 17 and 18., and there are some clinical data suggesting that the exon 13 andd 14 
mutations are still sensitive to sunitinib whereas mutations at exons 17 and 18 are not 
(Heinrich et al., 2008).  
Basing on these considerations mutational analyses are considered to be a needful 
requirement to predict the effectiveness of pharmacological therapy on GIST patient. 
For these reasons, it would be of great importance the molecular classification of  
GISTs, which both emphasizes the molecular contest of the tumor as well as provides  
a quick reference for syndromes with which stromal tumors may be associated  
(Table 8).  
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GIST type Response to pharmacological therapy 
KIT mutation  
 Exon 11 Excellent response to imatinib 
 Exon 9 Intermediate response to imatinib 
 Exon 13 Sensitive to imatinib in vitro 
 Exon 17 Sensitive to imatinib in vitro 
PDGFRǂ mutation  
 Exon 12 Sensitive to imatinib in vitro 
 Exon 18 D842V: poor response; other mutations are sensitive 
Wild type Poor response to imatinib 
Table 8. Molecular classification of GIST (Corless CL et al., 2001, modified) 
14. Methodologies to assess GISTs response to therapy 
As more GISTs are being resected following down-staging with imatinib therapy, there are 
increasing published data regarding the pathological changes induced by such therapy, 
although these data are still evolving.  
These changes can be divided into those representing GIST regressing with therapy and into 
those of GIST resistant to therapy. In the former case, the typical macroscopic appearance is 
a gelatinous cut surface with focal haemorrhagic and/or necrosis. Histologically, these 
features correspond with a hypocellular, mixoid and/or fibrotic stroma, containing 
scattered residual GIST cells with pyknotic nuclei and minimal cytoplasm. 
When compared with its pre-treated counterpart, an imatinib regressing GIST will typically 
shows reduced or absent CD117 immuno-positivity, reduced CD34 positivity and a 
reduction of mitotic activity and Ki67 labelling index.  
There is little documentation of whether GISTs demonstrating primary imatinib resistance 
show specific histopathological changes; by contrast, the range of pathological features 
associated with secondary resistance to imatinib has been more widely described.  
Radiologically, secondary resistance is often characterized by re-emergence of 2-[18F]fluoro-D-
glucose (FDG) uptake on positron emission tomography (PET) scan and/or peripheral 
thickening or nodule formation in a previously responding tumor on TC scan Mabille et al., 
2009; (Mabille et al., 2009; Van den Abbeele et al., 2008). This corresponds macroscopically with 
one or more solid area showing the above-mentioned regressing changes within the tumor. 
Some case reports described secondary resistant GISTs developing a more epithelioid 
appearance, with large cells containing abundant eosinophilic cytoplasm. However, there 
are doubts regarding the true significance of this phenomena.  
Actually, overall assessment of response to therapy in patients undergoing treatment for 
GISTs actually relies decrease of tumor density as observed on computed tomography, since 
tumor progression may present as change in size or density. In this context, it has been 
proposed a new set of response evaluation criteria in which tumor response is defined as a 
10% decreased in unidimensional tumor size or a 15% decrease in tumor density on 
tomography (Choi et al., 2007).  
15. GISTs prognosis 
Several clinical factors have been reported to define the prognosis of GISTs. Tumor tumor 
size, location in the fundus or gastroesophageal junction, coagulative necrosis, ulceration, 
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mucosal invasion and mitotic count have all been identified as unfavourable factors. In 
addition, male sex, high age, high Ki67 (or MIB-1) grade, desmin staining and incomplete 
surgical resection have been also shown to be factors having a wrong impact on the overall 
survivals (Ozguc et al., 2005). Moreover, it seems that patients with tumor rupture have a 
very high risk of recurrence, since tumor rupture taking place either spontaneously or at 
surgery increases the risk of intra-abdominal tumoral implants. Tumor rupture seems to be 
independent of the size and mitotic count (Rutkowski et al., 2007; Takahashi et al., 2007).  
Almost all small GISTs detected incidentally or through serial sectioning of surgical or 
autoptic specimens display an uniformly spindle cell morphology and are CD117+/CD34+; 
however, expression of CD34 is often lacking or is focal in the secondary compartment. It 
has been demonstrated that the secondary localization generally evolved from the 
corresponding lower-grade primary site through accumulation of additional chromosomal 
imbalances. This fact suggest that progression from low-grade to high-grade morphology, as 
well as eventual metastatic behaviour is driven by increasing chromosomal instability 
(Agaimy et al., 2009). In summary, it seems that sequential chromosomal alterations rather 
than KIT or PDGFRǂ mutations would drive the evolution to eventual GIST more 
aggressive behaviour (Agaimy et al., 2009). However, further studies are needed to clarify 
these correlations and link them to clinical outcome. 
Since additional prognostic factors are continuously proposed in the medical literature, the 
need of accurate risk stratification becomes increasingly urgent. Accurate risk stratification 
is crucial for the selection of patients who are most likely to benefit from pharmacological 
therapy (Demetri et al., 2007).  
16. Conclusions 
This review provides an overview on gastrointestinal stromal tumor. Pathogenesis, 
morphologic evaluation, immunohistochemical markers, risk assessment, molecular 
analyses and therapies, represent the basic elements of the present work, as well as the 
disquisition regarding the pharmacological approach to this neoplasia and the mechanisms 
of drug resistance. 
At a glance overview emerges how GISTs, from being poorly defined, treatment-resistant 
neoplasia become a well recognised, well understood and effectively treated neoplasia.  
In this context, progresses in understanding of GIST biology laid the foundation for the fist 
model of target therapy. GIST model is now widely adopted in programmes focusing on a 
variety of other solid tumors. 
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